# Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

> **NCT03623854** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Chordoma
- Locally Advanced Chordoma
- Metastatic Chordoma
- Unresectable Chordoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Relatlimab

## Key facts

- **NCT ID:** NCT03623854
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-03
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03623854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03623854, "Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03623854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*